Insight Molecular Diagnostics (IMDX) Liabilities and Shareholders Equity (2015 - 2026)

Insight Molecular Diagnostics has reported Liabilities and Shareholders Equity for 12 years, with the latest figure at $40.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 33.02% year-over-year to $40.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.6 million (down 33.17% YoY) and the FY2025 annual result came in at $25.8 million, down 26.58% from the prior year.
• Liabilities and Shareholders Equity improved to $40.4 million in Q1 2026 per IMDX's latest filing, from $25.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $171.1 million in Q2 2022 and troughed at $25.8 million in Q4 2025.
• A 5-year average of $80.8 million and a median of $74.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity increased 13.12% in 2022, then slumped 53.16% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $100.1 million in 2022, then dropped by 25.18% to $74.9 million in 2023, then plunged by 53.16% to $35.1 million in 2024, then fell by 26.58% to $25.8 million in 2025, then soared by 56.96% to $40.4 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $40.4 million, $25.8 million, and $43.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.